{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:15:31Z","timestamp":1740107731094,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003790","name":"Hiroshima University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003790","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to clarify the long-term safety and efficacy of rituximab (RTX) as a remission induction therapy following severe relapse in patients with antineutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis (AAV). We retrospectively collected the data of patients with severely relapsed AAV from a Japanese multicentre cohort. The primary exposure was RTX use; the primary outcome was complete remission (CR) proportions at week 24. Baseline characteristics were compared between the RTX and non-RTX groups. We performed multivariate logistic regression analysis and one-to-one propensity score matching analysis as a sensitivity analysis. Totally, 100 patients were enrolled: 52 in the RTX group and 48 in the non-RTX group. Baseline characteristics were comparable between the two groups, except for age, AAV subtype and ANCA serotype. The median age was 71 vs. 75\u00a0years, and the PR3-ANCA positivity rate was 44.2% vs. 18.8% in the RTX and non-RTX groups, respectively. No significant difference was observed in CR proportions at week 24 between the two groups (79.2% vs. 68.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.321), with an adjusted odds ratio of 1.27 (95% confidence interval [CI] 0.47\u20133.51). At week 48, CR proportions were significantly higher in the RTX group (91.7% vs. 64.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005), with an adjusted odds ratio of 2.95 (95% CI 0.97\u20139.91). Serious infection rates were lower in the RTX group than in the non-RTX group, with no statistically significant difference. RTX was not superior to conventional immunosuppressive therapies at week 24 but showed significantly favourable results at week 48 for severely relapsed AAV.<\/jats:p><jats:p><jats:table-wrap><jats:table><jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\"><jats:bold>Key Points<\/jats:bold><\/jats:td>\n                    <\/jats:tr>\n                    <jats:tr>\n                      <jats:td align=\"left\">\u2022 <jats:italic>RTX might be superior to traditional treatments as an induction therapy for severely relapsed AAV.<\/jats:italic>\u2022 <jats:italic>RTX has the potential to sustain long-term remission with fewer occurrences of infections in the treatment of severely relapsed AAV.<\/jats:italic><\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>","DOI":"10.1007\/s10067-024-07096-y","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T20:06:00Z","timestamp":1723493160000},"page":"3195-3204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody\u2013associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0558-8814","authenticated-orcid":false,"given":"Genki","family":"Kidoguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Mokuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Omura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Nakagomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Kadoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoho","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Kukida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Yamano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Yanagida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayuko","family":"Takatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshia","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Ito-Ihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Kawahito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of Japan Collaborative Registry of ANCA-Associated Vasculitis (J-CANVAS)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"7096_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching AR, Anders HJ, Basu N et al (2020) ANCA-associated vasculitis. Nat Rev Dis Primers 6:71. https:\/\/doi.org\/10.1038\/s41572-020-0204-y","journal-title":"Nat Rev Dis Primers"},{"key":"7096_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","volume":"5","author":"AD Salama","year":"2020","unstructured":"Salama AD (2020) Relapse in anti-neutrophil cytoplasm antibody (ANCA)\u2013associated vasculitis. Kidney Int Rep 5:7\u201312. https:\/\/doi.org\/10.1016\/j.ekir.2019.10.005","journal-title":"Kidney Int Rep"},{"key":"7096_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41584-018-0145-y","volume":"15","author":"D Nakazawa","year":"2019","unstructured":"Nakazawa D, Masuda S, Tomaru U, Ishizu A (2019) Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 15:91\u2013101. https:\/\/doi.org\/10.1038\/s41584-018-0145-y","journal-title":"Nat Rev Rheumatol"},{"key":"7096_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41584-018-0065-x","volume":"14","author":"M McClure","year":"2018","unstructured":"McClure M, Gopaluni S, Jayne D, Jones R (2018) B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. Nat Rev Rheumatol 14:580\u2013591. https:\/\/doi.org\/10.1038\/s41584-018-0065-x","journal-title":"Nat Rev Rheumatol"},{"key":"7096_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/mr\/roac150","volume":"33","author":"K Nagasaka","year":"2023","unstructured":"Nagasaka K, Amano K, Dobashi H et al (2023) Nation-wide cohort study of remission induction therapy using rituximab in Japanese patients with antineutrophil cytoplasmic antibody\u2013associated vasculitis: effectiveness and safety in the first 6 months. Mod Rheumatol 33:1117\u20131124. https:\/\/doi.org\/10.1093\/mr\/roac150","journal-title":"Mod Rheumatol"},{"key":"7096_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211\u2013220. https:\/\/doi.org\/10.1056\/NEJMoa0909169","journal-title":"N Engl J Med"},{"key":"7096_CR7","doi-asserted-by":"publisher","first-page":"e2220925","DOI":"10.1001\/jamanetworkopen.2022.20925","volume":"5","author":"S Thietart","year":"2022","unstructured":"Thietart S, Karras A, Augusto JF et al (2022) Evaluation of rituximab for induction and maintenance therapy in patients 75 years and older with antineutrophil cytoplasmic antibody\u2013associated vasculitis. JAMA Netw Open 5:e2220925. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.20925","journal-title":"JAMA Netw Open"},{"key":"7096_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semarthrit.2015.02.005","volume":"45","author":"H Timlin","year":"2015","unstructured":"Timlin H, Lee SM, Manno RL, Seo P, Geetha D (2015) Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum 45:67\u201369. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.02.005","journal-title":"Semin Arthritis Rheum"},{"key":"7096_CR9","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s10067-023-06644-2","volume":"42","author":"F Aqeel","year":"2023","unstructured":"Aqeel F, Xu L, Salas A et al (2023) Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly. Clin Rheumatol 42:2427\u20132435. https:\/\/doi.org\/10.1007\/s10067-023-06644-2","journal-title":"Clin Rheumatol"},{"key":"7096_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","volume":"79","author":"RM Smith","year":"2020","unstructured":"Smith RM, Jones RB, Specks U et al (2020) Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 79:1243\u20131249. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216863","journal-title":"Ann Rheum Dis"},{"key":"7096_CR11","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1002\/art.38788","volume":"66","author":"EM Miloslavsky","year":"2014","unstructured":"Miloslavsky EM, Specks U, Merkel PA et al (2014) Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheumatol 66:3151\u20133159. https:\/\/doi.org\/10.1002\/art.38788","journal-title":"Arthritis Rheumatol"},{"key":"7096_CR12","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1002\/art.24637","volume":"60","author":"RB Jones","year":"2009","unstructured":"Jones RB, Ferraro AJ, Chaudhry AN et al (2009) A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis. Arthritis Rheum 60:2156\u20132168. https:\/\/doi.org\/10.1002\/art.24637","journal-title":"Arthritis Rheum"},{"key":"7096_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/ard-2023-224472","volume":"83","author":"Y Ishikawa","year":"2024","unstructured":"Ishikawa Y, Tokutsu K, Nakayamada S et al (2024) Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis 83:103\u2013111. https:\/\/doi.org\/10.1136\/ard-2023-224472","journal-title":"Ann Rheum Dis"},{"key":"7096_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"7096_CR15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH et al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83:30\u201347. https:\/\/doi.org\/10.1136\/ard-2022-223764","journal-title":"Ann Rheum Dis"},{"key":"7096_CR16","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D et al (2009) Modification and validation of the birmingham vasculitis activity score, 3rd version. Ann Rheum Dis 68:1827. https:\/\/doi.org\/10.1136\/ard.2008.101279","journal-title":"Ann Rheum Dis"},{"key":"7096_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/rheumatology\/keu452","volume":"54","author":"F Alberici","year":"2015","unstructured":"Alberici F, Smith RM, Jones RB et al (2015) Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Rheumatology (Oxford) 54:1153\u20131160. https:\/\/doi.org\/10.1093\/rheumatology\/keu452","journal-title":"Rheumatology (Oxford)"},{"key":"7096_CR18","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-017-1321-1","volume":"19","author":"MD Morgan","year":"2017","unstructured":"Morgan MD, Szeto M, Walsh M et al (2017) Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. Arthritis Res Ther 19:129. https:\/\/doi.org\/10.1186\/s13075-017-1321-1","journal-title":"Arthritis Res Ther"},{"key":"7096_CR19","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/art.42556","volume":"75","author":"N Khoudour","year":"2023","unstructured":"Khoudour N, Delestre F, Jabot-Hanin F et al (2023) Association between plasma rituximab concentration and the risk of major relapse in antineutrophil cytoplasmic antibody\u2013associated vasculitides during rituximab maintenance therapy. Arthritis Rheumatol 75:2003\u20132013. https:\/\/doi.org\/10.1002\/art.42556","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07096-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07096-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07096-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:06:55Z","timestamp":1727672815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07096-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7096"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07096-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"5 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by the Ethics Committee for Epidemiological Research of Hiroshima University (approval number: E-2021\u20132465). This study was conducted in accordance with the ethical standards of the Declaration of Helsinki, and the requirement for written consent was waived because of the retrospective nature of the study. Approval dates and names of the ethics committees at participating centres are provided in Supplemental Table\u00a0.An abstract of the data from this study, limited to older individuals, has been published in the \u201c2023 EULAR Congress Abstract Book\u201d. Kidoguchi G, Yoshida Y, Watanabe H et al. (2023) AB0786 induction therapy with rituximab enables sustained remission in elderly patients with relapsed ANCA-associated vasculitis: a retrospective analysis from J-CANVAS, a Japanese multicentre-cohort. Ann Rheum Dis 82:1603\u20131604. .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"We disclose the following conflicts of interest with pharmaceutical companies promoting RTX or RTX biosimilars as outlined below. Yusuke Yoshida: speaker fees \u2014 Chugai. Takashi Kida: speaker fees \u2014 Chugai. Daiki Nakagomi: scholarship donations, speaker fees \u2014 Chugai. Naoho Takizawa: speaker fees \u2014 Chugai, Kyowa Hakko Kirin, Pfizer. Yuji Kukida: speaker fees \u2014 Chugai, Pfizer. Kiyoshi Matsui: research grants \u2014 Chugai. Masaru Kato: speaker fees \u2014 Chugai, Pfizer. Tomoaki Takata: speaker fees \u2014 Chugai; scholarship donations, speaker fees \u2014 Kyowa Hakko Kirin. Takafumi Ito: speaker fees \u2014 Chugai, Kyowa Hakko Kirin. Takashi Kawaguchi: speaker fees, consultancy \u2014 Chugai; speaker fees \u2014 Kyowa Hakko Kirin. Yutaka Kawahito: speaker fees, research grants \u2014 Chugai; speaker fees \u2014 Pfizer. Shintaro Hirata: speaker fees, consultancy fees, research grants \u2014 Chugai, Pfizer and additional relationships, including speaker fees, consultancy fees, research grants and honoraria with AbbVie; Asahi \u2014 Kasei Pharma; Astellas; AstraZeneca; Ayumi; Bristol Myers Squibb; Boehringer Ingelheim; Daiichi \u2014 Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Eli Lilly; Janssen; Nippon Shinyaku; Novartis; Otsuka; Taisho; Tanabe \u2014 Mitsubishi; and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}